The National Institutes of Health (NIH) National Cancer Institute has awarded a $4.5 million grant to Leuko to further develop PointCheck, the first solution to enable non-invasive white blood cell monitoring.

美国国立卫生研究院（NIH）国家癌症研究所（National Institutes of Health National Cancer Institute）向Leuko提供了450万美元的赠款，以进一步开发PointCheck，这是第一个实现无创白细胞监测的解决方案。

Funds from the SBIR Phase IIB grant will accelerate product development and generate clinical evidence to commercialize this platform technology. 'At Leuko, we are committed to deliver on our vision for non-invasive blood testing, which could transform how cancer patients and other immunocompromised populations are managed,' Leuko Co-Founder/CEO Carlos Castro-Gonzalez said.

来自SBIR IIB期拨款的资金将加速产品开发，并产生临床证据，将该平台技术商业化。”Leuko联合创始人/首席执行官卡洛斯·卡斯特罗·冈萨雷斯（CarlosCastroGonzalez）说，在Leuko，我们致力于实现无创血液检测的愿景，这可能会改变癌症患者和其他免疫功能低下人群的管理方式。

'Thanks to this NIH grant, we will advance to the next stage of clinical development and move closer to making this technology widely available to patients.'.

“多亏了美国国立卫生研究院的资助，我们将进入临床开发的下一阶段，并更接近于使这项技术广泛应用于患者。”。

White blood cell monitoring is particularly relevant for cancer patients who receive chemotherapy and other treatments that target cancer cells but can also destroy white blood cells, compromising the immune system. Such a compromise leads tens of thousands of cancer patients annually to contract dangerous infections that can turn deadly if unmanaged..

白细胞监测对于接受化疗和其他针对癌细胞的治疗的癌症患者尤其重要，但也可能破坏白细胞，损害免疫系统。这样的妥协每年导致成千上万的癌症患者感染危险的感染，如果不加以管理，这些感染可能会致命。。

Doctors currently monitor patients is through blood tests, which practically limit the frequency of monitoring. But Leuko's at-home, non-invasive monitor, PointCheck, can give doctors a more complete view of their patients’ health remotely. Rather than drawing blood, the device uses light to look through the skin at the top of the fingernail, and advanced algorithms to analyze and detect low white blood cell levels..

医生目前通过验血来监测患者，这实际上限制了监测的频率。但Leuko在家的无创监护仪PointCheck可以让医生远程更全面地了解患者的健康状况。该设备不需要抽血，而是使用光线透过指甲顶部的皮肤，并使用先进的算法来分析和检测低白细胞水平。。

By removing the need for a blood sample, Leuko enables at-home, and more frequent monitoring so at-risk patients can be identified early, enabling the care team to deploy preventive treatment that can avoid infections, reduce hospital admissions by 50%, and improve clinical outcomes.

通过消除对血液样本的需求，Leuko可以在家中进行更频繁的监测，以便尽早发现高危患者，使护理团队能够部署预防性治疗，避免感染，减少50%的住院率，并改善临床结果。

Leuko spun out from MIT and the Madrid M+Vision Consortium. Co-founded by Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro, the company is developing PointCheck, a platform technology to non-invasively measure blood parameters. For its first application, Leuko aims to improve clinical outcomes for more than 2 million cancer patients annually, reduce their chemotherapy-related hospital admissions by 50%, and save over $4 billion in healthcare costs.  .

Leuko从麻省理工学院和马德里M+Vision联盟分离出来。该公司由卡斯特罗·冈萨雷斯（CastroGonzalez）、伊恩·巴特沃斯（IanButterworth）、奥雷连·布夸德（AurelienBourquard）和阿尔瓦罗·桑切斯·费罗（AlvaroSanchezFerro）共同创立，目前正在开发PointCheck，这是一种无创测量血液参数的平台技术。对于其首次应用，Leuko旨在每年改善200多万癌症患者的临床结果，将其与化疗相关的住院率降低50%，并节省40多亿美元的医疗费用。。